Apolizumab

N/A

Report date: 2023/05/05 17:41:06

Base Information

Drug NameApolizumab
Drug Alias NameRemitogenHu1D10SMART 1D10 antibodyMonoclonal antibody SMART 1D10
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunostimulants
TargetsHLA-DR antigens-associated invariant chain
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPdl Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesStanford UniversityNational Cancer InstitutePdl Biopharma Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG